The 16 references in paper E. Kulaga A., E. Shakhnovich B., O. Kerbikov B., Е. Кулага А., Е. Шахнович Б., О. Кербиков Б. (2015) “РОЛЬ ТАРГЕТНОЙ ТЕРАПИИ В ЛЕЧЕНИИ РАСПРОСТРАНЕННОГО ГЕПАТОЦЕЛЛЮЛЯРНОГО РАКА // THE ROLE OF TARGETED THERAPY IN THE TREATMENT OF ADVANCED HEPATOCELLULAR CARCINOMA” / spz:neicon:modonc:y:2015:i:1:p:50-54

1
Sangiovanni A, Prati GM, Fasani P et al. The natural history of compensated cirrhosis due to hepatitis C virus a 17-year cohort study of 214 patients. Hepatology 2006; 43: 1303–10.
(check this in PDF content)
2
EASL-EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol 2012; 56: 908–43.
(check this in PDF content)
3
Bruix J, Sherman M. Management of Hepatocellular Carcinoma: An Update. Hepatology 2011; 53 (3).
(check this in PDF content)
4
Verslype C, Rosmorduc O, Rougier P. ESMO Guidelines Working Group. Hepatocellular carcinoma: ESMO–ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012; 23 (Suppl. 7): vii41–8.
(check this in PDF content)
5
http://nccn.org
(check this in PDF content)
6
Практические рекомендации по лекарственному лечению больных первичным раком печени Российского общества клинической онкологии (RUSSCO). Версия 2014; с. 243–52. / Prakticheskie rekomendatsii po lekarstvennomu lecheniiu bol'nykh pervichnym rakom pecheni Rossiiskogo obshchestva klinicheskoi onkologii (RUSSCO). Versiia 2014; s. 243–52. [in Russian]
(check this in PDF content)
7
Wilhelm S, Carter C, Lynch M et al. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Dis 2006; 5 (10): 835–44.
(check this in PDF content)
8
Abou-Alfa GK, Schwartz L, Ricci S et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006; 24 (26): 4293–300.
(check this in PDF content)
9
Abou-Alfa GK, Johanson P, Knox J et al. Preliminary results from Phase II, randomized, double-blind study of sorafenib plus doxorubicin vs. placebo plus doxorubicin in patients with advanced hepatocellular carcinoma. ECCO 14 – European Cancer Conference. Barselona, Spain, 23–27 Sept. 2007.
(check this in PDF content)
10
Cheng AL, Kang YK, Chen Z et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009; 10 (1): 25–34.
(check this in PDF content)
11
Llovet JM et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359 (4): 378–90.
(check this in PDF content)
12
Marrero J et al. Final analysis of GIDEON (Global Investigation of the rapeutic DEcisions in hepatocellular carcinoma and of its treatment with sorafeNib) in >3000 sorafenib-treated patients: clinical findings in patients with liver dysfunction. Poster presented at the Annual Meeting of the American Society of Clinical Oncology. May 31 – June 4 2013. Chicago, Illinois USA.
(check this in PDF content)
13
Faivre S, Raymond E, Boucher E et al. Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study. Lancet Oncol 2009; 10 (8): 794–800.
(check this in PDF content)
14
Johnson PJ, Qin S, Park JW et al. Brivanib vs. sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study. J Clin Oncol 2013; 31 (28): 3517–24.
(check this in PDF content)
15
Boige V, Malka D, Bourredjem A et al. Efficacy, safety, and biomarkers of single-agent bevacizumab therapy in patients with advanced hepatocellular carcinoma. Oncologist 2012; 17 (8): 1063–72.
(check this in PDF content)
16
Zhu AX, Kudo M, Assenat E et al. EVOLVE-1: Phase 3 study of everolimus for advanced HCC that progressed during or after sorafenib. Abstr. J Clin Oncol 2014; 32 (Suppl. 3): 172. сведения об авторах Шахнович Елена Борисовна – врач-онколог, ФГБУ Инсти
(check this in PDF content)